Diabetes Medicines Approved in the EU (EMA)

• 147medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 15Jul2026

  Liraglutide STADA

  Active substance: liraglutide

  EMEA/H/C/006615
• 15Jul2026

  Ablymico

  Active substance: liraglutide

  EMEA/H/C/006620
• 15Jul2026

  Vislyfa

  Active substance: ranibizumab

  EMEA/H/C/006926
• 19Jun2026

  Rexatilux

  Active substance: ranibizumab

  EMEA/H/C/006634
• 6May2026

  Bysumlog

  Active substance: insulin lispro

  EMEA/H/C/006158
• 27Apr2026

  Dazparda

  Active substance: insulin aspart

  EMEA/H/C/006187
• 26Mar2026

  Kayshild

  Active substance: semaglutide

  EMEA/H/C/006426
• 10Feb2026

  Ranluspec

  Active substance: ranibizumab

  EMEA/H/C/006502
• 9Jan2026

  Ondibta

  Active substance: insulin glargine

  EMEA/H/C/006136
• 8Jan2026

  Teizeild

  Active substance: teplizumab

  EMEA/H/C/005496
• 24Nov2025

  Kyinsu

  Active substance: insulin icodec;semaglutide

  EMEA/H/C/006279
• 21Nov2025

  Svariya (previously Rivaroxaban Koanaa)

  Active substance: rivaroxaban

  EMEA/H/C/006643
• 15Sep2025

  Eyluxvi

  Active substance: aflibercept

  EMEA/H/C/006282
• 18Aug2025

  Mynzepli

  Active substance: aflibercept

  EMEA/H/C/006438
• 18Aug2025

  Afiveg

  Active substance: aflibercept

  EMEA/H/C/006761

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Diabetes (ages 20–79)
• Diabetes (adults, WHO)
• Clinical trials: Diabetes
• Diabetes death rate

• Obesity
• Cardiovascular
• Eye health
• Hypertension
• Kidney health
• Biologics and biosimilars
• Maternal
• HIV
• Tuberculosis
• Pediatric